
### ü´Å Critical Care Medicine: Evaluation of Hypotension and Shock

#### ‚úÖ True Statements
1. **Shock** occurs when **systemic tissue perfusion** is insufficient to meet the body's **cellular metabolic demands** and usually manifests as **hypotension and organ dysfunction**.  
2. The presence of **hypotension alone** is **not diagnostic of shock**.  
3. **Blood pressure** should be interpreted in the context of **end-organ hypoperfusion findings** such as **altered mental status**, **skin mottling**, **increased capillary refill time**, **decreased urine output**, **tachycardia**, and **tachypnea**.  
4. Elevated **serum lactate** and **creatinine** levels, although nonspecific, may suggest **tissue hypoperfusion**.  
5. In **patients with cirrhosis**, **hypotension in the absence of shock** is common due to **splanchnic and systemic vasodilation** and **decreased responsiveness to intrinsic catecholamines**.  
6. In asymptomatic patients with **hypotension but no end-organ damage or hypoperfusion**, **reassurance without further evaluation** is appropriate.  
7. **Echocardiography (Echo)** is indicated in suspected **cardiogenic shock**, **pericardial tamponade**, or **acute valvular disease**, but not in asymptomatic patients without cardiac findings.  
8. **Crystalloid infusion** (such as **lactated Ringer solution**) is appropriate in **hypovolemia** and many forms of **shock**, but not in **asymptomatic euvolemic cirrhosis**, where it may worsen **ascites** or **edema**.  
9. **Vasopressin** is a potent **arteriolar vasoconstrictor** useful in **shock**, but not indicated in patients without shock.  
10. Initial management of most forms of **shock** focuses on **fluid resuscitation** rather than immediate vasopressor therapy.

#### üí¨ Extra
5. Hypotension in cirrhosis often reflects chronic vasodilatory physiology rather than acute circulatory collapse.  
8. Avoiding unnecessary crystalloids in cirrhosis prevents worsening ascites or peripheral edema.  
9. High doses of vasopressin may decrease cardiac output and cause myocardial ischemia.

#### üè∑Ô∏è Tags
#CriticalCare #Shock #Hypotension #Cirrhosis #FluidResuscitation #Vasopressors #Echocardiography

#### üìö Reference
Vincent JL, De Backer D. Circulatory shock. *N Engl J Med*. 2013;369:1726-34. PMID: 24171518 doi:10.1056/NEJMra1208943

#### üÜî Question ID
CCMCQ24011

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Critical Care Medicine ‚Äî Common ICU Conditions, Shock

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Shock** occurs when **systemic tissue perfusion** is inadequate, leading initially to **reversible tissue injury** and eventually to **cellular dysfunction and death** if uncorrected.  
2. The four primary mechanisms of **shock** are **hypovolemic (decreased circulating volume)**, **cardiogenic (pump failure)**, **obstructive (circulatory obstruction)**, and **distributive (inappropriate vasodilation)**.  
3. **Hypotension alone** should not be considered diagnostic of **end-organ hypoperfusion**.  
4. Diagnosis of **shock type** requires a combination of **physical examination**, **laboratory results**, and **ancillary studies**.  
5. **Point-of-care ultrasonography** is increasingly used to assess **shock**, including **echocardiography**, **vascular**, **lung**, and **abdominal ultrasonography**.  
6. **Pulmonary artery catheters** show limited benefit and possible harm with routine use, but may help in select patients requiring precise **cardiopulmonary pressure** or **cardiac output** measurement.  
7. **Pulse contour analysis**, **pulse pressure variation**, and **stroke volume variation** can estimate **cardiac output**, particularly in **intubated, passively respiring patients** receiving **tidal volumes &gt;8 mL/kg**.  
8. **Distributive shock** is most often caused by **sepsis**, but other disease states may present similarly.  
9. Initial treatment of **distributive shock** focuses on **fluid resuscitation**, preferably with **crystalloids** over **colloids** due to cost considerations and safety.  
10. Balanced crystalloid solutions (e.g., **lactated Ringer solution**) are generally favored over **0.9% saline**, although superiority is not conclusively proven.  
11. If fluids are inadequate in distributive shock, **vasopressor support** is warranted, with selection based on **comorbidities** and **shock etiology**.  
12. **Hypovolemic shock** results from decreased **intravascular volume**, reducing **preload**, **ventricular filling**, and **stroke volume**.  
13. Treatment of **hypovolemic shock** involves **volume replacement** and control of the **source of fluid or blood loss**.  
14. In **hemorrhagic shock**, initial stabilization may use **intravenous fluids**, but **erythrocyte transfusion** is often required to prevent ischemia.  
15. In stable ICU patients with hemorrhage, maintain **hemoglobin &gt;7 g/dL (70 g/L)**; higher thresholds may be required in **active bleeding** or **ischemia**.  
16. **Cardiogenic shock** most commonly results from **myocardial infarction**, with other causes including **arrhythmias** and **valvular disease**.  
17. **Echocardiography** is essential in evaluating **cardiogenic shock**.  
18. **Revascularization** improves survival in **ST-elevation myocardial infarction with cardiogenic shock**, regardless of ischemia duration.  
19. First-line vasopressors in **cardiogenic shock** include **norepinephrine** and **dobutamine**, with advanced support (e.g., **venoarterial ECMO**, **intra-aortic balloon pump**) as potential bridges.  
20. **Obstructive shock** arises from extracardiac forces impairing cardiac output, including **cardiac tamponade**, **tension pneumothorax**, and **acute pulmonary embolism**.  
21. **Point-of-care ultrasonography** can rapidly identify **pneumothorax**, **pericardial tamponade**, or **pulmonary embolism** in suspected **obstructive shock**.  
22. Most cases of **obstructive shock** can be rapidly reversed if promptly identified.

#### üí¨ Extra
2. These four categories are not mutually exclusive; overlap can occur.  
10. Balanced crystalloid preference appears in contemporary sepsis guidance, but mortality benefit remains uncertain.  
15. Higher transfusion thresholds may be considered in **acute coronary syndrome**.  
19. Advanced support devices are not definitive therapy but serve as bridges until revascularization or recovery.  
20. Hemodynamics of obstructive shock often mimic cardiogenic shock, requiring careful diagnostic distinction.

#### üè∑Ô∏è Tags
#Shock #CriticalCare #DistributiveShock #HypovolemicShock #CardiogenicShock #ObstructiveShock #Ultrasound #Resuscitation #Sepsis

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="Algorithm for the Evaluation of Shock.svg" alt="Flowchart: Algorithm for the Evaluation of Shock with decision nodes for hypotension, mean arterial pressure, echocardiography, and management steps." />
  <figcaption><strong>Algorithm for the Evaluation of Shock.</strong> Echo = echocardiogram; MAP = mean arterial pressure; SBP = systolic blood pressure.</figcaption>
</figure>

---

#### üóæ Supplemental Tables

<!-- Common Clinical Findings in Patients With Shock -->
<table>
  <caption><strong>Common Clinical Findings in Patients With Shock</strong></caption>
  <thead>
    <tr><th>Finding</th></tr>
  </thead>
  <tbody>
    <tr><td>Altered mentation</td></tr>
    <tr><td>Capillary refill time &gt;2 s</td></tr>
    <tr><td>Elevated serum lactate (&gt;3 mEq/L [3 mmol/L])</td></tr>
    <tr><td>Hypotension (SBP &lt;90 mm Hg) or &gt;30 mm Hg drop in SBP from baseline</td></tr>
    <tr><td>Mottled skin</td></tr>
    <tr><td>Tachycardia (heart rate &gt;100/min)</td></tr>
    <tr><td>Tachypnea (respiration rate &gt;20/min)</td></tr>
    <tr><td>Urine output &lt;0.5 mL/kg/h</td></tr>
  </tbody>
</table>
<p><em>SBP = systolic blood pressure.</em></p>

#### ‚úÖ True Statements (from Table: Common Clinical Findings in Patients With Shock)
1. **Shock** may present with **altered mentation**.  
2. **Capillary refill time greater than 2 seconds** is a clinical finding in **shock**.  
3. **Serum lactate &gt;3 mEq/L (3 mmol/L)** is listed as a **shock** finding.  
4. **Hypotension** is defined in this table as **systolic blood pressure (SBP) &lt;90 mm Hg** or a **&gt;30 mm Hg SBP drop from baseline**.  
5. **Mottled skin** is a clinical finding in **shock**.  
6. **Tachycardia** (heart rate **&gt;100/min**) is a clinical finding in **shock**.  
7. **Tachypnea** (respiratory rate **&gt;20/min**) is a clinical finding in **shock**.  
8. **Urine output &lt;0.5 mL/kg/h** is a clinical finding in **shock**.  

---

<!-- Selected Causes of Shock -->
<table>
  <caption><strong>Selected Causes of Shock</strong></caption>
  <thead>
    <tr><th>Category</th><th>Examples</th></tr>
  </thead>
  <tbody>
    <tr><td><strong>Distributive</strong></td><td>Anaphylaxis; Drugs (peripheral vasodilators, nitrates); Sepsis; Spinal injury (usually above T4 level); Adrenal insufficiency</td></tr>
    <tr><td><strong>Hypovolemic</strong></td><td>Acute blood loss (trauma, GI bleeding, surgery, uterine bleeding, obstetric, retroperitoneal bleeding, aortic rupture); Crush injury, rhabdomyolysis; Cutaneous losses (burns, toxic epidermal necrolysis, erythroderma, excessive sweating); Drugs (diuretics, laxatives); GI losses (vomiting/diarrhea); Kidney losses (diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, adrenal insufficiency, post-ATN osmotic diuresis)</td></tr>
    <tr><td><strong>Cardiogenic</strong></td><td>Arrhythmia (tachycardia, bradycardia); Heart failure; Pulmonary hypertension with right ventricular failure; Myocardial infarction; Valvular heart disease (critical stenosis, severe insufficiency, valve perforation, papillary muscle or chordae rupture); Ventricular septal rupture</td></tr>
    <tr><td><strong>Obstructive</strong></td><td>Abdominal compartment syndrome; Atrial myxoma; Constrictive pericarditis; Pericardial tamponade; Pulmonary embolism; Severe dynamic hyperinflation (e.g., excessive PEEP); Tension pneumothorax</td></tr>
  </tbody>
</table>
<p><em>ATN = acute tubular necrosis; GI = gastrointestinal; PEEP = positive end-expiratory pressure; T4 = fourth thoracic vertebra.</em></p>

#### ‚úÖ True Statements (from Table: Selected Causes of Shock)
1. **Distributive shock** causes include **anaphylaxis**, **peripheral vasodilator drugs**, **sepsis**, **high spinal cord injury** (usually above **T4**), and **adrenal insufficiency**.  
2. **Hypovolemic shock** causes include **hemorrhage**, **cutaneous fluid losses**, **gastrointestinal losses**, **renal losses** (including **post‚Äìacute tubular necrosis osmotic diuresis**), and **drug-induced losses** (diuretics, laxatives).  
3. **Cardiogenic shock** causes include **arrhythmias**, **heart failure**, **pulmonary hypertension with right ventricular failure**, **myocardial infarction**, **critical valvular disease**, and **ventricular septal rupture**.  
4. **Obstructive shock** causes include **abdominal compartment syndrome**, **pericardial tamponade**, **pulmonary embolism**, **tension pneumothorax**, **severe dynamic hyperinflation**, **constrictive pericarditis**, and **atrial myxoma**.  

---

<!-- Selection of Vasopressors and Inotropes -->
<table>
  <caption><strong>Selection of Vasopressors and Inotropes</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Type of Shock</th>
      <th>Receptor Target</th>
      <th>Primary Effect</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Angiotensin II</td>
      <td>Distributive</td>
      <td>AT II</td>
      <td>&uarr; SVR</td>
      <td>Role still being defined</td>
    </tr>
    <tr>
      <td>Dobutamine (inotrope)</td>
      <td>Cardiogenic; Distributive</td>
      <td>&beta;1, &beta;2</td>
      <td>&uarr; Inotropy</td>
      <td>First choice for cardiogenic shock without hypotension; may be added to norepinephrine for septic shock with depressed cardiac function</td>
    </tr>
    <tr>
      <td>Milrinone (inotrope)</td>
      <td>Cardiogenic</td>
      <td>PDE3 (inhibitor)</td>
      <td>&uarr; Inotropy</td>
      <td>Alternative agent in cardiogenic shock refractory to other agents</td>
    </tr>
    <tr>
      <td>Dopamine (high-dose)</td>
      <td>Cardiogenic</td>
      <td>D, &alpha;1, &beta;1</td>
      <td>&uarr; SVR, &uarr; Inotropy</td>
      <td>Associated with increased mortality compared with norepinephrine in distributive shock; use only in cases of severe bradycardia in septic shock</td>
    </tr>
    <tr>
      <td>Dopamine (low-dose)</td>
      <td>Cardiogenic</td>
      <td>D, &beta;1</td>
      <td>&uarr; Inotropy, &uarr; HR</td>
      <td>Not recommended to augment renal blood flow</td>
    </tr>
    <tr>
      <td>Epinephrine</td>
      <td>Cardiogenic; Distributive; Hypovolemic</td>
      <td>&alpha;1, &alpha;2, &beta;1, &beta;2</td>
      <td>&uarr; SVR, &uarr; Inotropy</td>
      <td>First choice in anaphylactic (distributive) shock; may be added to norepinephrine and vasopressin in persistent septic shock; may be used as a single agent in septic shock with depressed cardiac function</td>
    </tr>
    <tr>
      <td>Norepinephrine</td>
      <td>Cardiogenic; Distributive; Hypovolemic</td>
      <td>&alpha;1, &alpha;2, &beta;1</td>
      <td>&uarr; SVR, &uarr; Inotropy</td>
      <td>First choice in cardiogenic, distributive, and hypovolemic shock</td>
    </tr>
    <tr>
      <td>Phenylephrine</td>
      <td>Distributive</td>
      <td>&alpha;1</td>
      <td>&uarr; SVR</td>
      <td>Alternative agent for distributive shock when tachyarrhythmias preclude use of first-line agents</td>
    </tr>
    <tr>
      <td>Vasopressin</td>
      <td>Distributive; Hypovolemic</td>
      <td>V</td>
      <td>&uarr; SVR</td>
      <td>May be added to norepinephrine in persistent septic (distributive) shock; no role in other shock states</td>
    </tr>
  </tbody>
</table>
<p><em>AT II = angiotensin type II; D = dopamine; HR = heart rate; PDE3 = phosphodiesterase 3; SVR = systemic vascular resistance; V = vasopressin.</em></p>

#### ‚úÖ True Statements (from Table: Selection of Vasopressors and Inotropes)
1. **Norepinephrine** is listed as the **first-choice vasopressor** in **cardiogenic**, **distributive**, and **hypovolemic** shock.  
2. **Epinephrine** is the **first-choice agent** in **anaphylactic (distributive) shock**.  
3. **Vasopressin** may be **added to norepinephrine** in **persistent septic shock** and has **no role** in **other shock states** per this table.  
4. **Dobutamine** is a **first-choice inotrope** for **cardiogenic shock without hypotension** and may be **added to norepinephrine** in **septic shock with depressed cardiac function**.  
5. **High-dose dopamine** is associated with **increased mortality** compared with norepinephrine in **distributive shock** and should be **reserved for severe bradycardia in septic shock**.  
6. **Low-dose dopamine** is **not recommended** to **augment renal blood flow**.  
7. **Phenylephrine** is an **alternative** for **distributive shock** when **tachyarrhythmias** limit use of first-line agents.  

---

<!-- Clinical Presentations of Common Causes of Obstructive Shock -->
<table>
  <caption><strong>Clinical Presentations of Common Causes of Obstructive Shock</strong></caption>
  <thead>
    <tr>
      <th>Cause</th>
      <th>Possible Findings on Presentation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PE</td>
      <td>Signs of elevated right atrial pressure (including JVD and lower extremity edema); Clear pulmonary examination</td>
    </tr>
    <tr>
      <td>Tamponade</td>
      <td>JVD; Pulsus paradoxus; Distant heart sounds</td>
    </tr>
    <tr>
      <td>Tension pneumothorax</td>
      <td>Absent lung sounds on affected side of chest</td>
    </tr>
  </tbody>
</table>
<p><em>JVD = jugular venous distention; PE = pulmonary embolism.</em></p>

#### ‚úÖ True Statements (from Table: Clinical Presentations of Common Causes of Obstructive Shock)
1. **Pulmonary embolism (PE)** in **obstructive shock** may present with **elevated right atrial pressure signs**, including **jugular venous distention** and **lower extremity edema**, with a **clear pulmonary examination**.  
2. **Cardiac tamponade** in **obstructive shock** may present with **jugular venous distention**, **pulsus paradoxus**, and **distant heart sounds**.  
3. **Tension pneumothorax** in **obstructive shock** may present with **absent breath sounds on the affected side**.  

